Nishtala, PS and Salahudeen, MS and Hilmer, SN, Anticholinergics: theoretical and clinical overview, Expert opinion on drug safety, 15, (6) pp. 753-768. ISSN 1474-0338 (2016) [Refereed Article]
Copyright 2016 Informa UK Limited, trading as Taylor & Francis Group
Introduction: Anticholinergics are a class of medicines that block the neurotransmitter, acetylcholine, in the brain and peripheral tissues. Medicines with anticholinergic activity are widely prescribed for and used by older people for various medical conditions. One-third to one-half of the medicines commonly prescribed for older people have anticholinergic activity. Several studies have reported anticholinergic burden to be a predictor of cognitive and functional impairments in older people.
Areas covered:This article exemplifies the theoretical and clinical aspects of medicines with anticholinergic activity, including pharmacology (definition of medicines that possess anticholinergic activity, antimuscarinic receptors, therapeutic and adverse effects), epidemiology, measures and effects of cumulative anticholinergic burden in older adults, and clinical recommendations. In addition, the gaps in the literature have been identified for future research.
Expert opinion: Many medicines that are commonly prescribed to older people have a degree of anticholinergic activity that can contribute to anticholinergic burden. Anticholinergic burden, measured in several ways that consider number, dose and/or degree of anticholinergic activity of medicines, has shown to be a predictor of adverse health and functional outcomes. The anticholinergic burden on older people should be minimised by avoiding, reducing dose and deprescribing medicines with anticholinergic activity where clinically possible.
|Item Type:||Refereed Article|
|Keywords:||Anticholinergic; anticholinergic medicine; antimuscarinic; anticholinergic burden; anticholinergic adverse effect; acetylcholine; older people; muscarinic receptor; anticholinergic risk scale; anticholinergic mechanism; anticholinergic overview; anti|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Pharmacology and pharmaceutical sciences|
|Research Field:||Clinical pharmacy and pharmacy practice|
|Objective Group:||Evaluation of health and support services|
|Objective Field:||Evaluation of health outcomes|
|UTAS Author:||Salahudeen, MS (Dr Mohammed Salahudeen)|
|Web of Science® Times Cited:||57|
Repository Staff Only: item control page